Current Protocols Editorial Board: Cytometry
 |
J. Paul Robinson (Managing Editor) Dr. Joe Harford serves as Director of the Office of International Affairs (OIA) of the National Cancer Institute. In this capacity, he has responsibility for a number of bilateral and multilateral interactions between the NCI and foreign cancer research institutions. His office also tracks all funding going to foreign investigators through NCI grants and contracts as well as other forms of international collaboration. Dr. Harford serves as the Chair of the Strategic Advisory Group of the Ireland-Northern Ireland-NCI Cancer Consortium and as NCI liaison to the Middle East Cancer Consortium, the US-Japan Cooperative Cancer Research Program, and the International Network for Cancer Treatment and Research. Dr. Harford also represents the United States as a member of the Governing Council of the WHO's International Agency for Research on Cancer and as a member of the Board of Trustees of the Human Frontier Science Program, an international non-governmental, nonprofit association devoted to the promotion of basic research. Dr. Harford received his undergraduate degree in chemistry from Ohio University and his Ph.D. in biochemistry from the University of Maryland School of Medicine. He first came to the NIH in 1979 as a post-doctoral fellow and remained until 1993 at which time he was Deputy Director of the Cell Biology and Metabolism within NICHD. Dr. Harford's research efforts for this period involved receptor-mediated processes and the post-transcriptional regulation of genes involved in cellular iron metabolism. From 1993 to 1996, Dr. Harford directed the research efforts of RiboGene, Inc., a privately held biotechnology company in the San Francisco Bay Area. There, his research team focused upon unusual features of the process of protein synthesis in infectious pathogens and cancer. Under the direction of Dr. Harford, RiboGene, Inc. developed several high-throughput screens for new classes of therapeutic agents and obtained a number of Small Business Innovative Research grants from the NIH. Dr. Harford is a co-inventor on two issued U.S. patents. Dr. Harford currently chairs the NCI Technology Review Group with responsibility for actions related to the Institute's intellectual property. Dr. Harford has published over 100 scientific papers and served on the editorial boards for a number of scientific journals. He served as the Series Editor for Modern Cell Biology, a series of thematic volumes dealing with topics in molecular and cell biology. He edited the volume mRNA Metabolism and Post-transcriptional Gene Regulation for this series. Dr. Harford is one of the founding editors for Current Protocols in Cell Biology. |
 |
Zbigniew Darzynkiewicz Zbigniew Darzynkiewicz, M.D., Ph.D., is the Director of the Brander Cancer Research Institute at the New York Medical College and the Professor of Medicine and Pathology at the same College. Formerly, Dr. Darzynkiewicz was the Professor of Cell Biology and Genetics at Cornell University Medical School, a Member of the Sloan-Kettering Institute for Cancer Research, the Head of the Experimental Cell Research Laboratory, and the Director of the Flow Cytometry Core Facility Network, all at the Sloan-Kettering Institute, New York. Dr. Darzynkiewicz is the Editor of the Experimental Cell Research and Cell Proliferation and a Member of the Editorial Boards of 10 other scientific journals. He is the past President of The Cell Kinetics Society and also past President of the International Society for Analytical Cytology (ISAC; >2000 members from over 60 countries). Dr. Darzynkiewicz's research concentrates on cell biology with particular focus on cancer cell growth and the regulatory mechanisms associated with cell growth and progression through the cell cycle. He has developed several techniques that have world-wide application, to analyze metabolic parameters of the cell related to cell cycle kinetics, cell sensitivity to anti-tumor drugs and apoptosis. He was a recipient of the prestigious MERIT grant award from the National Institute of Health (NIH). Since 1972 his research has been continuously supported by the grants from NIH and other agencies. He was also a recipient of a grant from NASA to develop new technologies for cell staining and analysis applicable to the micro-gravity conditions of the Space Station. Dr. Darzynkiewicz has authored over 400 original publications and over 75 chapters and reviews in books devoted to the subject of cell growth, regulation of the cell cycle and apoptosis, and has authored and/or edited 11 books. He holds five US patents, several are pending. His publications have been cited over 10.000 times in the scientific literature. He consults several pharmaceutical companies and is on the Board of Scientific Advisors of the Alfacell Co. (Bloomfield, N.J.) and PharmaSeq Co. (Princeton, N.J) Dr. Darzynkiewicz received his M.D. (with the highest honors) in 1960 and his Ph.D. in 1966 from the Medical School of Warsaw, Warsaw, Poland. He completed his post-graduate studies at the State University of New York at Buffalo and the Medical Nobel Institute of Karolinska Institute, Stockholm, Sweden. Since 1974, he has been associated with the Sloan-Kettering Institute for Cancer Research, and since 1990, he has been with New York Medical College, Valhalla, New York. Website: http://www.geocities.com/z_darzynkiewicz |
 |
Robert Hoffman Dr. Hoffman has a B.S. in physics from the University of Illinois, Urbana, and a Ph.D. in physics from Virginia Polytechnic Institute and State University. He began his career in analytical instrumentation as a post doctoral fellow in the flow cytometry group at the Los Alamos National Laboratory in 1976. While at Los Alamos he also consulted for Coulter Electronics. He next worked nine years for Ortho Diagnostic Systems in several scientific and technical management positions in flow cytometry and automated hematology. Since 1987 he has been with BD Biosciences, where he has provided instrument concepts and helped develop flow cytometers including the FACSCalibur, FACSCount and FACSArray. Responsibilities at BD included Director of Instrument Engineering and Director of Instrumentation Technology. He is currently a BD Fellow in the Advanced Technology Group. Dr. Hoffman has been a member of four Clinical and Laboratory Standards Institute subcommittees and has helped teach six continuing education courses in flow cytometry. In 2006 he was elected a Fellow of the American Institute of Medical and Biological Engineering. Since 2006 he has been an editor for Current Protocols in Cytometry. He has 18 patents and over 40 publications in the field of flow cytometry. Recent interests have focused on simpler instruments, performance characterization and improved performance standards. |
 |
John Nolan John Nolan is Professor at the La Jolla Bioengineering Institute in La Jolla, California. He received his BS degrees in Biology and Chemistry from the University of Illinois and his PhD in Biochemistry from Penn State University. He did post-doctoral research at Los Alamos National Laboratory, and remained there for ten years, the last three as Director of the National Flow Cytometry Resource. His research involves the quantitative analysis of cellular and molecular systems, including the development of flow cytometry instrumentation and assays. ISAC service: Member, 1990-present; Scientific Advisory Committee 2002-04; Councilor, 2002-06; Chair, Scientific Advisory Committee, 2004-08; Congress Organizing Committee 2006, 2008. |
 |
Alberto Orfao Dr. Alberto Orfao holds degrees in medicine and surgery at the University of Salamanca (1984) and the University of Lisbon (1985), and obtained a doctorate degree in 1987 from the University of Salamanca. He is currently Professor and Director of General of the University Cytometry. Its activities focus on research in the clinical area and especially in the field of immune system and cancer, as is proven by over 100 publications in international journals over the past five years. Among other positions Dr. Orfao has been president of the Iberian Cytometry (Iberian Society of Cytometry) (1995-1999), Chairman of the Committee for Standardization in clinical flow cytometry (The Standardization Committee on Clinical Flow Cytometry of the International Federation of Clinical Chemistry) of the International Federation of Clinical Chemistry (1994-1997). He is currently a member of the European Group of Characterization of leukemia (European Group for the Immunological characterization of leukemia). |
 |
Peter S. Rabinovitch Dr. Rabinovitch's primary interests are in cell cycle, cell proliferation, and the role of genomic instability in the aging process and in early events leading to neoplasia. Dr. Rabinovitch studies alterations in cell proliferation and genetic instability in aging and in neoplastic progression. He is examining the connection between free-radical theories of aging, altered redox status and the basis of the decreased proliferative potential of aged somatic cells. In particular, the progeroid disease Werner Syndrome is being studied as a potential model of the connection between altered DNA repair, genetic instability, and aging. Dr. Rabinovitch is also the PI for the renewal of the long-standing program project in aging begun by Dr. George Martin. This renewal focuses on mouse models with augmented antioxidant and antimutator capacity. Overexpression of catalase targeted to the mitochondria is the most promising model to date, with extension of both mean and maximal lifespan. Dr. Rabinovitch is also using the premalignant gastrointestinal diseases ulcerative colitis and Barrett's esophagus as models of the relationship between immortalization, genetic instability, and the clinical risk of progression to cancer. He has a special interest in using cytometric technologies to study the cell cycle and genetic instability. Dr. Rabinovitch is Professor of Pathology, Joint Full Member of the Fred Hutchinson Cancer Research Center, and Director of the Nathan Shock Center of Excellence in the Basic Biology of Aging at the University of Washington. Website: http://www.pathology.washington.edu/research/labs/rabinovitch/members/peter.php |
 |
Simon Watkins Dr. Simon Watkins is the Founder and Director of the Center for Biologic Imaging at the University of Pittsburgh and a member of the Pittsburgh Cancer Institute. He is also the Director of the Graduate Program and a Professor (with tenure) within the Department of Cell Biology and Physiology. In addition to his responsibilities to the university, Dr. Watkins serves as a member on the Research advisory Board of Children's Hospital. Dr. Watkins received his Ph.D. in Neurobiology from Newcastle University in England in 1983. He also holds a B.S.C. in Zoology from Hull University in England. Following his graduate studies, Dr. Watkins was appointed as a Research Fellow at Pasteur Institute in Paris, France, within the Department of Molecular Biology. Immediately prior to arriving at the university, he was a Research Fellow and Research Associate at the Harvard Medical School Dana-Farber Cancer Institute. Understanding the processes of development, assembly and integration of the dystrophin cytoskeleton and its potential role(s) in establishing and maintaining normal muscle function is a primary research interest of Dr. Watkins. For his work concerning this topic, he has been featured in several publications. Currently, he is continuing efforts to develop a better understanding of these processes as well as defining what goes wrong in a number of related diseases including Duchenne muscular dystrophy (dystrophin deficiency), congenital muscular dystrophy (merosin deficiency) and the sarcoglycanopathies. Website: http://www.mirm.pitt.edu/people/bios/Watkins1.asp |
Most Popular Tools
Beyond the Bench
READ OUR EDITORS' BLOG for news, commentaries, and the latest developments in methods both in and out of the lab.
Discussion Boards
See what authors, experts, and peers are discussing.
